Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ramipril + candesartan
- Development stage
- Phase 4
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Combination therapy of ramipril (an ACE inhibitor) and candesartan (an angiotensin II receptor blocker) that targets the renin-angiotensin system through two distinct mechanisms. This combination has been shown to improve blood pressure control, endothelial function, insulin resistance, and plasma adipocytokine profiles to a greater extent than either drug as monotherapy.
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)ACE (Angiotensin Converting Enzyme)
Beyond the preview
Go deeper on ramipril + candesartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ramipril + candesartan.